New vaccine aims to block more Cancer-Causing viruses
NCT ID NCT06688058
Summary
This early-stage study is testing the safety and immune response of an experimental HPV vaccine called V540D in 72 healthy adults. The vaccine is designed to protect against the same 9 HPV types as the current Gardasil 9 vaccine, plus additional cancer-causing types. Researchers will compare side effects and immune responses between people receiving the new vaccine and those receiving the standard vaccine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alliance for Multispecialty Research, LLC ( Site 0003)
Kansas City, Missouri, 64114, United States
-
Alliance for Multispecialty Research, LLC ( Site 0004)
Knoxville, Tennessee, 37920, United States
-
Research Centers of America ( Hollywood ) ( Site 0001)
Hollywood, Florida, 33024, United States
-
Velocity Clinical Research, Savannah ( Site 0005)
Savannah, Georgia, 31406, United States
Conditions
Explore the condition pages connected to this study.